DARPA Wants Medical Gear That Works on Soldiers and Dogs Alike. The BARK SBIR Is Open.

A military working dog handler operating in a contested environment carries two medical kits. One for himself. One for his dog. The tourniquet that stops his bleeding will not fit a canine limb. The autoinjector loaded with nerve agent antidote is dosed for a 180-pound human, not a 70-pound Belgian Malinois. The vital signs monitor strapped to his wrist cannot read a dog's core body temperature. Every piece of species-specific equipment adds weight, complexity, and cognitive load to a handler already operating under extreme stress.

DARPA thinks this is a solvable engineering problem. On May 6, 2026, the agency opened BARK — Broadening Availability of Regimens for K-9s — a Small Business Innovation Research topic that funds the development of medical products designed to work across both human and canine patients. Proposals are due June 3, 2026.

The concept sounds simple. The execution is anything but.

4,000 Wounded Dogs and a Data Gap

Over two decades of operations in Iraq and Afghanistan, more than 4,000 military working dogs suffered combat injuries. These animals are not pets — they are trained assets valued at $50,000 to $100,000 each, with capabilities that no technology has replicated. A 2010 Pentagon study found that MWDs detect 89 percent of improvised explosive devices, compared to 50 percent for mechanical detection systems. They clear buildings faster than robots, track human scent through terrain where electronic sensors fail, and provide a psychological deterrent that no piece of equipment can match.

When these dogs are wounded, the medical response has historically been improvised. Field handlers apply human medical supplies in ways they were never designed for, estimate drug dosages based on rough weight calculations, and evacuate injured animals through the same casualty chain designed for humans — but without the monitoring equipment, blood products, or treatment protocols optimized for canine physiology.

The Defense Health Agency chartered the K9 Combat Casualty Care Committee (K9C4) in 2021 to develop clinical practice guidelines and training programs for canine battlefield medicine. The DHA also launched a Military Working Dog Trauma Registry to capture injury and treatment data that had never been systematically recorded. Until that registry became operational, the military did not have basic epidemiological data on what injuries MWDs sustain, what treatments they receive in the field, or what outcomes those treatments produce.

Meanwhile, the U.S. Army Medical Materiel Development Activity (USAMMDA) at Fort Detrick has been developing freeze-dried canine blood plasma — a lightweight, shelf-stable product that can be reconstituted with sterile water and administered at the point of injury. As USAMMDA health science product manager Dr. Cliff Snyder put it: "Without access to this type of product, some dogs will die that could have survived."

BARK builds on all of this work — but takes a fundamentally different approach.

The Interoperability Thesis

Most military medical research treats human and canine medicine as parallel tracks. FSHARP develops synthetic blood for humans. USAMMDA develops freeze-dried plasma for dogs. The K9C4 writes canine-specific treatment guidelines. Each program advances its species-specific mission independently.

BARK inverts that logic. Instead of building separate products for separate species, it asks: what medical technologies can be designed from the ground up to work across both? The thesis is that interoperable medical products — a single tourniquet that adjusts to human and canine anatomy, a single drug delivery system that modulates dosing by species, a single sensor that reads vital signs from either patient — would reduce the total equipment burden while improving care for both.

This is not a minor distinction. A handler carrying one medical kit instead of two saves weight and simplifies decision-making under fire. A medic who can use the same monitoring system on a wounded soldier and a wounded dog does not need to switch between incompatible interfaces during a mass casualty event. A supply chain that stocks one universal autoinjector instead of two species-specific versions is simpler, cheaper, and less likely to create shortages in the field.

DARPA has identified four categories of dual-use medical products that BARK performers should target.

Four Technical Domains

Sensors and monitoring devices. BARK seeks physiological monitoring systems — core body temperature, blood pressure, heart rate, respiratory rate — designed to function on both human and canine patients. The challenge is not the sensing technology itself but the form factor. Human vital signs monitors assume a wrist, a finger, or a chest strap. Canine anatomy does not accommodate any of these attachment points well. A dual-use sensor must either adapt its form factor at point of care or use a sensing modality (non-contact infrared, acoustic, or radar-based) that is geometry-independent.

Adjustable medical devices. Splints, backboards, tourniquets, and mechanical ventilators that can be rapidly reconfigured in the field for use across different anatomies. The key requirement is speed — a handler applying a tourniquet to a wounded dog in a firefight cannot spend 30 seconds adjusting a complex mechanism. The device must transition between human and canine configurations in seconds, ideally through a single intuitive action.

Chemical, biological, radiological, and nuclear countermeasures. Interoperable medical countermeasures and personal protective equipment that protect against CBRN threats across species. This is perhaps the most technically challenging domain. Nerve agent antidotes, for example, require different dosing for humans and dogs, and the delivery mechanisms (autoinjectors for humans versus intramuscular injection for dogs) differ in form factor, needle gauge, and injection site. A dual-use system must solve the dosing, delivery, and protection problems simultaneously.

Universal drug delivery. Mechanisms that can modulate pharmaceutical dosing to enable the same drug product to be used across species. This does not necessarily mean developing new drugs — DARPA explicitly discourages new drug discovery under BARK except in exceptional circumstances. Instead, the focus is on delivery platforms that can take existing FDA-approved pharmaceuticals and administer them at species-appropriate doses through a single device.

What DARPA Will Not Fund

The BARK solicitation draws sharp lines around what it considers innovation. "Testing existing products, including collection of data to titrate dosages or support label expansion of a marketed product" does not meet the program's innovation threshold. This is a research and development program, not a regulatory pathway accelerator.

Proposals that amount to taking a human tourniquet and testing it on dogs, or taking a canine blood pressure cuff and validating it on humans, will not be competitive. DARPA wants new engineering — products conceived from the start for dual-species use, not existing products adapted after the fact.

The program is structured in two phases. Phase I covers research, design, and preliminary prototyping, with testing limited to in vitro and in silico work. No human or animal subject testing is permitted during Phase I. Phase II moves to pre-clinical testing, user evaluation in operational contexts, and development of a regulatory strategy for both species.

Phase III — the commercialization and transition phase — is where the dual-use thesis pays its largest dividends. DARPA explicitly identifies civilian applications spanning emergency medicine, veterinary care for companion and service animals, law enforcement K-9 units, and search-and-rescue operations. A tourniquet that adjusts between human and canine limbs has obvious applications for every police department and fire department that operates with working dogs.

How Proposals Are Evaluated

White papers are evaluated on four criteria, in descending order of importance.

Proposed concept. Reviewers assess the technical design, mechanistic justification, and any preliminary data supporting feasibility. Proposals that include proof-of-concept data — even from adjacent applications — will outscore those that present theoretical arguments alone.

Concept of employment. How will the product be used in practice? What is the clinical indication? What is the prevalence of the condition being treated? What advantages does the proposed product offer over existing commercial alternatives used independently for each species?

Path to market. FDA regulatory strategy is critical. A product that works on both humans and dogs must navigate both FDA human medical device or drug approval and FDA veterinary product approval. Proposals that demonstrate awareness of the dual regulatory pathway and propose a realistic timeline will score higher.

Scalability. Production costs, ease of deployment, training requirements for end users, and storage and maintenance needs. A brilliant prototype that costs $10,000 per unit and requires a biomedical engineer to operate will not transition to field use.

Who Should Apply

The ideal BARK proposer has expertise spanning biomedical engineering, veterinary medicine, and military medical device development. But the SBIR structure deliberately opens the competition to small businesses that may not have all three — the point is to fund innovative approaches from companies that bring fresh thinking to problems the established defense medical community has not solved.

Companies working on point-of-care diagnostics, wearable sensor platforms, adjustable orthopedic devices, smart drug delivery systems, or CBRN protective equipment should evaluate BARK carefully. The dual-use requirement adds complexity, but it also opens a market that extends far beyond military procurement — civilian veterinary medicine, law enforcement, and emergency services represent substantial commercial opportunities for products that genuinely work across species.

The submission window closes June 3, 2026, through the Defense SBIR/STTR Innovation Portal. For small businesses exploring DARPA SBIR opportunities across the biological technologies portfolio — including the related SWiFT blood transfusion topic — Granted tracks open solicitations across all DoD components and can surface matching opportunities as they are released.